skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation

Abstract

Purpose: The aim of this study was twofold: to determine whether the dose-volume metrics are valuable in predicting radiation pneumonitis (RP) in small-cell lung cancer (SCLC) patients treated with accelerated hyperfractionated radiotherapy and chemotherapy (AHFRT + CT); and to clarify how AHFRT influences the risk of RP in comparison to conventional once-daily radiotherapy and chemotherapy (QDRT + CT). Methods and Materials: Study subjects were 43 patients with SCLC treated with AHFRT + CT. Radiotherapy was delivered at 1.5 Gy/fraction (fr) twice daily to 45 Gy/30 fr/3 weeks. We analyzed the relation between RP incidence and several dosimetric factors. We also compared this series data with our previously published data from lung cancer patients treated with QDRT + CT. Results: Radiation pneumonitis Grades 1, 2, and 3 were observed in 28 patients, 7 patients, and 1 patient, respectively. Univariate analysis revealed that the percentage of lung volume receiving more than 15 Gy, 20 Gy, and 30 Gy (V15, V20, V30) and normal tissue complication probability were of predictive value for the development of RP. The 12-month cumulative incidences of RP greater than Grade 2 were 0%, 7.1%, 25%, and 42.9% in patients with a V20 of {<=}20%, 21-25%, 26-30%, and {>=}31%,more » respectively. These incidences were lower than that of our patients treated with QDRT + CT. Conclusions: Dosimetric factors are valuable in predicting RP in SCLC patients treated with AHFRT + CT. Regarding the incidence of RP, AHFRT appears to have some advantage over QDRT.« less

Authors:
 [1];  [1];  [2];  [2];  [1];  [1];  [1];  [1];  [1]
  1. Department of Radiology, Hyogo Medical Center for Adults, Akashi, Hyogo (Japan)
  2. Department of Respiratory Medicine, Hyogo Medical Center for Adults, Akashi, Hyogo (Japan)
Publication Date:
OSTI Identifier:
20793388
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 64; Journal Issue: 4; Other Information: DOI: 10.1016/j.ijrobp.2005.09.025; PII: S0360-3016(05)02716-1; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CHEMOTHERAPY; HEALTH HAZARDS; LUNGS; NEOPLASMS; PATIENTS; PNEUMONITIS; RADIATION DOSES; RADIOTHERAPY

Citation Formats

Tsujino, Kayoko, Hirota, Saeko, Kotani, Yoshikazu, Kado, Tetsuji, Yoden, Eisaku, Fujii, Osamu, Soejima, Toshinori, Adachi, Shuji, and Takada, Yoshiki. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation. United States: N. p., 2006. Web. doi:10.1016/J.IJROBP.2005.0.
Tsujino, Kayoko, Hirota, Saeko, Kotani, Yoshikazu, Kado, Tetsuji, Yoden, Eisaku, Fujii, Osamu, Soejima, Toshinori, Adachi, Shuji, & Takada, Yoshiki. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation. United States. https://doi.org/10.1016/J.IJROBP.2005.0
Tsujino, Kayoko, Hirota, Saeko, Kotani, Yoshikazu, Kado, Tetsuji, Yoden, Eisaku, Fujii, Osamu, Soejima, Toshinori, Adachi, Shuji, and Takada, Yoshiki. 2006. "Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation". United States. https://doi.org/10.1016/J.IJROBP.2005.0.
@article{osti_20793388,
title = {Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation},
author = {Tsujino, Kayoko and Hirota, Saeko and Kotani, Yoshikazu and Kado, Tetsuji and Yoden, Eisaku and Fujii, Osamu and Soejima, Toshinori and Adachi, Shuji and Takada, Yoshiki},
abstractNote = {Purpose: The aim of this study was twofold: to determine whether the dose-volume metrics are valuable in predicting radiation pneumonitis (RP) in small-cell lung cancer (SCLC) patients treated with accelerated hyperfractionated radiotherapy and chemotherapy (AHFRT + CT); and to clarify how AHFRT influences the risk of RP in comparison to conventional once-daily radiotherapy and chemotherapy (QDRT + CT). Methods and Materials: Study subjects were 43 patients with SCLC treated with AHFRT + CT. Radiotherapy was delivered at 1.5 Gy/fraction (fr) twice daily to 45 Gy/30 fr/3 weeks. We analyzed the relation between RP incidence and several dosimetric factors. We also compared this series data with our previously published data from lung cancer patients treated with QDRT + CT. Results: Radiation pneumonitis Grades 1, 2, and 3 were observed in 28 patients, 7 patients, and 1 patient, respectively. Univariate analysis revealed that the percentage of lung volume receiving more than 15 Gy, 20 Gy, and 30 Gy (V15, V20, V30) and normal tissue complication probability were of predictive value for the development of RP. The 12-month cumulative incidences of RP greater than Grade 2 were 0%, 7.1%, 25%, and 42.9% in patients with a V20 of {<=}20%, 21-25%, 26-30%, and {>=}31%, respectively. These incidences were lower than that of our patients treated with QDRT + CT. Conclusions: Dosimetric factors are valuable in predicting RP in SCLC patients treated with AHFRT + CT. Regarding the incidence of RP, AHFRT appears to have some advantage over QDRT.},
doi = {10.1016/J.IJROBP.2005.0},
url = {https://www.osti.gov/biblio/20793388}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 4,
volume = 64,
place = {United States},
year = {Wed Mar 15 00:00:00 EST 2006},
month = {Wed Mar 15 00:00:00 EST 2006}
}